相似文献
1
Role of the intestinal mucosa in acute gastrointestinal GVHD.
Blood. 2016 Nov 17;128(20):2395-2402. doi: 10.1182/blood-2016-06-716738.
2
Role of the intestinal mucosa in acute gastrointestinal GVHD.
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):119-127. doi: 10.1182/asheducation-2016.1.119.
3
Novel Insights Into the Mechanism of GVHD-Induced Tissue Damage.
Front Immunol. 2021 Aug 27;12:713631. doi: 10.3389/fimmu.2021.713631. eCollection 2021.
4
Crypt loss is a marker of clinical severity of acute gastrointestinal graft-versus-host disease.
Am J Hematol. 2007 Oct;82(10):881-6. doi: 10.1002/ajh.20976.
5
Pathology of graft-versus-host disease in the gastrointestinal tract.
Hum Pathol. 2009 Jul;40(7):909-17. doi: 10.1016/j.humpath.2009.04.001.
6
Intestinal Microbiota Influence Immune Tolerance Post Allogeneic Hematopoietic Cell Transplantation and Intestinal GVHD.
Front Immunol. 2019 Jan 17;9:3179. doi: 10.3389/fimmu.2018.03179. eCollection 2018.
7
Intestinal microbiota-related effects on graft-versus-host disease.
Int J Hematol. 2015 May;101(5):428-37. doi: 10.1007/s12185-015-1781-5. Epub 2015 Mar 27.
8
Gut decontamination during allogeneic hematopoietic stem cell transplantation and the risk of acute graft-versus-host disease.
Bone Marrow Transplant. 2018 Aug;53(8):1061-1064. doi: 10.1038/s41409-018-0131-7. Epub 2018 Feb 28.
9
Fecal microbiota transplantation in the treatment of intestinal steroid-resistant graft-versus-host disease: two case reports and a review of the literature.
J Int Med Res. 2020 Jun;48(6):300060520925693. doi: 10.1177/0300060520925693.
10
Recurrent spontaneous gastrointestinal graft-versus-host disease in autologous hematopoietic stem cell transplantation.
Clin Lymphoma Myeloma Leuk. 2010 Feb;10(1):E17-21. doi: 10.3816/CLML.2010.n.012.
引用本文的文献
1
The Long-Acting Glucagon-Like Peptide-2 Analog Apraglutide Enhances Intestinal Protection and Survival After Chemotherapy and Allogeneic Transplantation in Mice.
Ann Transplant. 2024 Nov 5;29:e945249. doi: 10.12659/AOT.945249.
2
Intestinal and Extraintestinal Findings of Graft-versus-Host Disease on CT: A Case Series with Radiological and Histopathological Correlations.
Biomedicines. 2024 Jul 8;12(7):1516. doi: 10.3390/biomedicines12071516.
3
Acute Steroid-Refractory Gastrointestinal Graft-Versus-Host Disease Is Not Associated With Significant Differences in Gut Taxonomic Composition Compared to Steroid-Sensitive Gastrointestinal Graft-Versus-Host Disease Immediately Before Onset of Disease.
Transplant Cell Ther. 2024 Feb;30(2):237.e1-237.e9. doi: 10.1016/j.jtct.2023.11.006. Epub 2023 Nov 7.
4
From support to therapy: rethinking the role of nutrition in acute graft-versus-host disease.
Front Immunol. 2023 Jun 8;14:1192084. doi: 10.3389/fimmu.2023.1192084. eCollection 2023.
5
Adjunctive Dietary Therapy Is Associated With Improved Gastrointestinal Symptoms in Steroid-Refractory Gastrointestinal Graft-Versus-Host Disease: A Case Series.
JPGN Rep. 2022 May 9;3(2):e203. doi: 10.1097/PG9.0000000000000203. eCollection 2022 May.
6
Faecal microbiota transplantation to prevent complications after allogeneic stem cell transplantation for haematological malignancies: a study protocol for a randomised controlled phase-II trial (the FMT-allo study).
BMJ Open. 2023 May 2;13(5):e068480. doi: 10.1136/bmjopen-2022-068480.
7
The Absence of IL-12Rβ2 Expression on Recipient Nonhematopoietic Cells Diminishes Acute Graft-versus-Host Disease in the Gastrointestinal Tract.
J Immunol. 2023 Feb 15;210(4):486-495. doi: 10.4049/jimmunol.2200120.
8
The Gut Bacteria Dysbiosis Contributes to Chronic Graft-Versus-Host Disease Associated With a Treg/Th1 Ratio Imbalance.
Front Microbiol. 2022 Sep 8;13:813576. doi: 10.3389/fmicb.2022.813576. eCollection 2022.
9
A Promising Insight: The Potential Influence and Therapeutic Value of the Gut Microbiota in GI GVHD.
Oxid Med Cell Longev. 2022 May 5;2022:2124627. doi: 10.1155/2022/2124627. eCollection 2022.
10
Resolution of Inflammation in Acute Graft-Versus-Host-Disease: Advances and Perspectives.
Biomolecules. 2022 Jan 5;12(1):75. doi: 10.3390/biom12010075.
本文引用的文献
1
Inflammation and the Intestinal Barrier: Leukocyte-Epithelial Cell Interactions, Cell Junction Remodeling, and Mucosal Repair.
Gastroenterology. 2016 Oct;151(4):616-32. doi: 10.1053/j.gastro.2016.07.008. Epub 2016 Jul 18.
2
Variable responses of human microbiomes to dietary supplementation with resistant starch.
Microbiome. 2016 Jun 29;4(1):33. doi: 10.1186/s40168-016-0178-x.
3
Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis.
Nat Immunol. 2016 Jun 21;17(7):765-74. doi: 10.1038/ni.3489.
4
Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD.
Blood. 2016 Jul 21;128(3):427-39. doi: 10.1182/blood-2015-12-684142. Epub 2016 May 24.
5
Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice.
Sci Transl Med. 2016 May 18;8(339):339ra71. doi: 10.1126/scitranslmed.aaf2311.
6
Programming of Intestinal Epithelial Differentiation by IL-33 Derived from Pericryptal Fibroblasts in Response to Systemic Infection.
Cell Rep. 2016 May 24;15(8):1743-56. doi: 10.1016/j.celrep.2016.04.049. Epub 2016 May 12.
7
How colonization by microbiota in early life shapes the immune system.
Science. 2016 Apr 29;352(6285):539-44. doi: 10.1126/science.aad9378.
8
Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantation.
Bone Marrow Transplant. 2016 Aug;51(8):1087-92. doi: 10.1038/bmt.2016.66. Epub 2016 Mar 21.
9
Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease.
Nat Immunol. 2016 May;17(5):505-513. doi: 10.1038/ni.3400. Epub 2016 Mar 21.
10
Partial restoration of the microbiota of cesarean-born infants via vaginal microbial transfer.
Nat Med. 2016 Mar;22(3):250-3. doi: 10.1038/nm.4039. Epub 2016 Feb 1.
Zotero 插件